aTyr Pharma to Discuss Lung Disease Candidate with FDA in April.

aTyr Pharma, a San Diego-based biotech, lost around 8% on Tuesday after announcing a meeting with the FDA in April to discuss its lead asset, efzofitimod, for lung disease. The company's shares fell in September after a similar meeting with the FDA. The FDA meeting in April is a key milestone for aTyr Pharma, and investors will be watching for any updates on the progress of efzofitimod.